Sio Capital Management, LLC
Sio Capital Management, LLC reported 57 US-listed holdings worth $583.5 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Anteris Technologies Global (9.4%), Cencora, Inc. (8.4%) and Maximus, Inc. (6.6%). Against the quarter before, it opened 15 positions, added to 10, trimmed 21 and sold out of 31.
Reported holdings$583.5M-15.9% on Q1 2026
Positions57-16 on Q1 2026
The largest ten50.1%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
OpenedAdded toTrimmed
The 14 largest of its 57 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +34.1% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Its reported holdingsThe S&P 500
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Opened 15Added 10Held 11Trimmed 21Sold out 31
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 15
- Allogene Therapeutics Inc. ALLO$27.7 million
- Globus Medical Inc. GMED$23.8 million
- Ideaya Biosciences Inc. IDYA$17.9 million
- Cigna Group CI$15.9 million
- Viatris Inc. VTRS$15.2 million
- Regeneron Pharmaceuticals, Inc. REGN$11.2 million
- Bristol-Myers Squibb Co. BMY$11.1 million
- Medtronic plc MDT$11.1 million
and 7 more in the table below
Added to 10
- Cencora, Inc. COR+72,694 shares · +72%
- Senseonics Hldgs Inc. Com SENS+1.5 million shares · +1276%
- Zimmer Biomet Holdings, Inc. ZBH+68,832 shares · +110%
- Sanofi SNY+124,529 shares · +52%
- Oruka Therapeutics Inc. ORKA+44,622 shares · +34%
- Tyra Biosciences Inc. TYRA+89,876 shares · +15%
- GSK plc GSK+50,821 shares · +13%
- Anteris Technologies Global AVR+163,019 shares · +3%
and 2 more in the table below
Trimmed 21
- ICON plc ICLR-218,172 shares · -71%
- Dianthus Therapeutics Inc. DNTH-310,791 shares · -84%
- Waystar Holding Corp. WAY-716,402 shares · -44%
- ANI Pharmaceuticals Inc. ANIP-168,238 shares · -63%
- Celcuity Inc. CELC-83,821 shares · -43%
- Sionna Therapeutics Inc SION-166,532 shares · -57%
- Abbott Laboratories ABT-57,918 shares · -31%
- Vir Biotechnology, Inc. VIR-423,346 shares · -28%
and 13 more in the table below
Sold out of 31
- Corcept Therapeutics Inc. CORT$27.2 million last quarter
- LivaNova plc LIVN$26.8 million last quarter
- Embecta Corp EMBC$16.3 million last quarter
- Abivax SA ABVX$15.1 million last quarter
- Haemonetics Corp. HAE$12.4 million last quarter
- Teleflex Inc. TFX$11.3 million last quarter
- Biomarin Pharmaceutical Inc. BMRN$11.0 million last quarter
- Structure Therapeutics Inc. GPCR$10.1 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Anteris Technologies Global AVR | 5.5M | $54.6 million | 9.36% | +163.0K |
| Cencora, Inc. COR | 173.6K | $49.1 million | 8.42% | +72.7K |
| Maximus, Inc. MMS | 715.3K | $38.5 million | 6.59% | -53.6K |
| Allogene Therapeutics Inc. ALLO | 13.3M | $27.7 million | 4.75% | new |
| Globus Medical Inc. GMED | 301.8K | $23.8 million | 4.09% | new |
| GSK plc GSK | 436.7K | $22.9 million | 3.92% | +50.8K |
| Tyra Biosciences Inc. TYRA | 695.3K | $22.2 million | 3.81% | +89.9K |
| Waystar Holding Corp. WAY | 925.8K | $19.0 million | 3.26% | -716.4K |
| Ideaya Biosciences Inc. IDYA | 480.4K | $17.9 million | 3.07% | new |
| Oruka Therapeutics Inc. ORKA | 177.1K | $16.9 million | 2.89% | +44.6K |
| Cigna Group CI | 57.8K | $15.9 million | 2.73% | new |
| Sanofi SNY | 364.2K | $15.5 million | 2.66% | +124.5K |
| ICON plc ICLR | 88.2K | $15.3 million | 2.63% | -218.2K |
| Viatris Inc. VTRS | 954.3K | $15.2 million | 2.60% | new |
| Cross Ctry Healthcare Inc. CCRN | 1.1M | $14.5 million | 2.49% | no change |
| Rapport Therapeutics Inc. RAPP | 307.7K | $12.8 million | 2.20% | -59.2K |
| Abbott Laboratories ABT | 128.7K | $11.7 million | 2.00% | -57.9K |
| Celcuity Inc. CELC | 110.0K | $11.5 million | 1.97% | -83.8K |
| Zimmer Biomet Holdings, Inc. ZBH | 131.4K | $11.3 million | 1.94% | +68.8K |
| Regeneron Pharmaceuticals, Inc. REGN | 18.0K | $11.2 million | 1.92% | new |
| Bristol-Myers Squibb Co. BMY | 193.5K | $11.1 million | 1.91% | new |
| Medtronic plc MDT | 142.5K | $11.1 million | 1.91% | new |
| Vir Biotechnology, Inc. VIR | 1.1M | $11.0 million | 1.88% | -423.3K |
| Senseonics Hldgs Inc. Com SENS | 1.6M | $9.0 million | 1.55% | +1.5M |
| Eyepoint Pharmaceuticals Inc. EYPT | 623.1K | $8.9 million | 1.53% | -98.7K |
| Cybin Inc. HELP | 1.3M | $8.6 million | 1.47% | new |
| ANI Pharmaceuticals Inc. ANIP | 97.3K | $8.1 million | 1.38% | -168.2K |
| Protara Therapeutics Inc. TARA | 1.9M | $7.3 million | 1.26% | -48.0K |
| Relmada Therapeutics Inc. RLMD | 1.0M | $6.9 million | 1.19% | +38.6K |
| Tango Therapeutics Inc. TNGX | 208.5K | $6.5 million | 1.12% | new |
| Aquestive Therapeutics Inc. AQST | 1.5M | $6.2 million | 1.06% | -436.7K |
| Dianthus Therapeutics Inc. DNTH | 59.3K | $5.8 million | 0.99% | -310.8K |
| Sionna Therapeutics Inc SION | 127.8K | $5.6 million | 0.96% | -166.5K |
| Ocular Therapeutix Inc. OCUL | 539.5K | $5.3 million | 0.91% | -429.1K |
| Zenas Biopharma Inc. ZBIO | 208.6K | $5.3 million | 0.91% | -123.2K |
| Bright Minds Biosciences Inc. DRUG | 74.0K | $5.2 million | 0.89% | -12.1K |
| Onkure Therapeutics Inc OKUR | 1.1M | $4.9 million | 0.84% | no change |
| Savara Inc. SVRA | 617.7K | $3.8 million | 0.65% | +3.8K |
| PMV Pharmaceuticals Inc. PMVP | 2.6M | $3.5 million | 0.60% | -442.4K |
| Aveanna Healthcare Hldgs Inc. AVAH | 369.0K | $3.2 million | 0.54% | new |
| Ovid Therapeutics Inc. OVID | 1.0M | $2.7 million | 0.46% | -247.0K |
| Immunome Inc. IMNM | 124.2K | $2.6 million | 0.45% | -40.9K |
| AN2 Therapeutics Inc. ANTX | 529.9K | $2.6 million | 0.44% | -127.3K |
| Serina Therapeutics Inc. SER | 1.0M | $1.9 million | 0.33% | no change |
| Aligos Therapeutics Inc. ALGS | 327.2K | $1.9 million | 0.32% | no change |
| Ibio Inc. Com IBIO | 904.3K | $1.6 million | 0.27% | no change |
| Xilio Therapeutics Inc. XLO | 152.5K | $1.5 million | 0.25% | no change |
| Artivion, Inc. AORT | 48.5K | $1.1 million | 0.19% | new |
| Bridgebio Oncology Therapeutics Ord BBOT | 130.6K | $995,385 | 0.17% | no change |
| Tela Bio Inc. TELA | 636.3K | $477,225 | 0.08% | no change |
| Adagio Med Hldgs Inc. ADGM | 699.0K | $455,461 | 0.08% | -589.5K |
| NeuroOne Medical Technologies Corporat NMTC | 82.8K | $251,612 | 0.04% | new |
| Enveric Biosciences Inc. ENVB | 180.0K | $248,400 | 0.04% | new |
| Modular Med Inc. MODD | 26.2K | $117,855 | 0.02% | no change |
| QT Imaging Hldgs Inc. QTI | 15.2K | $62,011 | 0.01% | new |
| Rocket Pharmaceuticals Inc. RCKTW | 400.0K | $1,480 | 0.00% | no change |
| Humacyte Inc. HUMAW | 50.0K | $477 | 0.00% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read more
Change is shares against its 13F for the quarter before; the 31 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| Sellas Life Sciences Group I SLS | Puts | 1.2M | $18.2 million |
| Hims & Hers Health, Inc. HIMS | Calls | 75.0K | $2.6 million |
2 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.